Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Phenylketonuria · Achondroplasia

BioMarin Pharmaceutical Australia

BioMarin Pharmaceutical Australia Pty Ltd

BioMarin Pharmaceutical Australia patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
770 Lindaro Street, San Rafael, CA 94901, US HQ
1997 Founded
3,171 Employees
TGA registrant Type
Company details
Status
Public
HQ
770 Lindaro Street, San Rafael, CA 94901, US
Founded
1997
Employees
3,171
Programs
12
Drugs
19
Patents
12
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

BioMarin Pharmaceutical Australia patents

12 pharmaceutical patents indexed for BioMarin Pharmaceutical Australia. 0 expire within 24 months.

BioMarin Pharmaceutical Australia has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

12 patents

Patent portfolio

  1. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11911446

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11590204

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10646550

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9907834

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9216178

    Dry blend formulation of tetrahydrobiopterin

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8735392

    Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt

    Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8420650

    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

    Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8198242

    Variants of C-type natriuretic peptide

    Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8012976

    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

    Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8003126

    Stable tablet formulation

    Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7566462

    Stable tablet formulation

    Expires Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does BioMarin Pharmaceutical Australia have?

12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do BioMarin Pharmaceutical Australia patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.